Clinical Trial Update: Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update testing Telaglenastat and Sapanisertib in advanced non-small cell lung cancer with brain and leptomeningeal metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Leptomeningeal Metastasis
• Non-small Cell Lung Cancer

Drugs mentioned

• Sapanisertib (sapanisertib)
• Telaglenastat (telaglenastat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Leptomeningeal Neoplasm, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING